Research Analysts Offer Predictions for OBIO Q3 Earnings

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Investment analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Orchestra BioMed in a research note issued on Wednesday, August 12th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.41) for the quarter, down from their previous estimate of ($0.39). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Orchestra BioMed’s FY2026 earnings at ($1.52) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.42) EPS, Q3 2027 earnings at ($0.40) EPS and FY2027 earnings at ($1.63) EPS.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.01. Orchestra BioMed had a negative return on equity of 127.86% and a negative net margin of 184.60%.The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.14 million.

Several other research analysts also recently commented on the stock. Wall Street Zen downgraded shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Piper Sandler reaffirmed an “overweight” rating and set a $10.00 price objective (up from $9.00) on shares of Orchestra BioMed in a report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Orchestra BioMed in a research report on Friday, July 17th. B. Riley Financial dropped their price objective on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Finally, Barclays lifted their price target on Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $13.00.

Orchestra BioMed Trading Up 0.7%

NASDAQ:OBIO opened at $4.45 on Friday. The business has a fifty day moving average price of $4.01 and a 200-day moving average price of $4.11. The company has a debt-to-equity ratio of 0.35, a current ratio of 7.03 and a quick ratio of 7.01. Orchestra BioMed has a one year low of $2.20 and a one year high of $5.42. The firm has a market capitalization of $267.44 million, a price-to-earnings ratio of -5.24 and a beta of 0.50.

Institutional Trading of Orchestra BioMed

Several large investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Orchestra BioMed in the 2nd quarter valued at $10,832,000. Vanguard Group Inc. increased its position in Orchestra BioMed by 28.0% during the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after purchasing an additional 324,558 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Orchestra BioMed during the third quarter worth about $3,386,000. Pathstone Holdings LLC purchased a new position in Orchestra BioMed during the third quarter worth about $2,495,000. Finally, Geode Capital Management LLC boosted its holdings in Orchestra BioMed by 22.4% in the 4th quarter. Geode Capital Management LLC now owns 473,363 shares of the company’s stock valued at $1,965,000 after purchasing an additional 86,564 shares during the last quarter. 53.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Orchestra BioMed

In other news, insider Darren Sherman sold 15,000 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $4.09, for a total transaction of $61,350.00. Following the sale, the insider directly owned 1,154,327 shares of the company’s stock, valued at $4,721,197.43. This represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.50% of the stock is owned by insiders.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.